INDV 6-K
Indivior Pharmaceuticals, Inc. (INDV)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of October 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
EXHIBIT INDEX
| Exhibit<br>No. | Description<br>of Exhibit |
|---|---|
| 99.1 | Announcement sent to the London Stock Exchange on October 15, 2024,<br>titled “Notice of Results”. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Indivior PLC | |
|---|---|
| Date: October 15, 2024 | /s/<br>Kathryn Hudson |
| Name:<br>Kathryn Hudson | |
| Title:<br>Company Secretary |
a1339i
Exhibit 99.1
Indivior to Announce Year-to-Date and Q3 2024 Results and Host Webcast on October 24th
Slough, UK, and Richmond, VA, October 15, 2024 - Indivior PLC (NASDAQ/LSE: INDV) today announced that it will release its year-to-date and Q3 2024 results on October 24th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.
Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 1:00 p.m. London time (8:00 a.m. U.S. Eastern) on October 24th.
Access to the Live Webcast Presentation:
The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins.
The webcast link: https://edge.media-server.com/mmc/p/ppm4ske8
Participants may access the presentation telephonically by registering with the following link:
https://register.vevent.com/register/BId4d5b45a6f3e4291ba42150c1620fc64
(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
A replay of the presentation will be available at www.indivior.com.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs approximately 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/ company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or [email protected]
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or [email protected]